{
  "docId": "019de073-aaaa-768c-937f-f768840b87a6",
  "docSlug": "9b8664e841ca83938179aa04bf759b1d",
  "documentTitle": "BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides",
  "authorId": "brainstorm-cell-therapeutics",
  "authorName": "Brainstorm Cell Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 15,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The chart displays the first principal component for each pathway over 20 weeks, comparing NurOwn and Placebo groups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-aaaa-768c-937f-f768840b87a6/9",
  "deckHref": "/decks/019de073-aaaa-768c-937f-f768840b87a6",
  "deckJsonHref": "/decks/019de073-aaaa-768c-937f-f768840b87a6.json",
  "deckAnchorHref": "/decks/019de073-aaaa-768c-937f-f768840b87a6#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Principal Component analysis over 20 weeks for NurOwn vs Placebo",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82f9ec13-974c-4200-9179-f8eb55467e95",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "list",
      "text": "Neuroinflammation decreased with NurOwn; Placebo Neuroinflammation levels remain high. Neurodegeneration decreases with NurOwn; Placebo Neurodegeneration levels remain elevated. Neuroprotection increased with NurOwn treatment; Placebo Neuroprotective levels remain low.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26b3d738-b42b-4952-aefe-eca4ada7773f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.05,
        "y": 0.52
      },
      "kind": "list",
      "text": "Biomarkers driving Principal Component Analysis: Neuroinflammation (CHI3L1, Chit-1; IP-10, MCP-1, Trem2; 63% variation), Neurodegeneration (NfL, UCH-L1, pNfH; 75% variation), Neuroprotection (Follistatin, VEGF, BDNF; Clusterin; 67% variation)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b29f9bcf-af66-4687-8220-56935867c239",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.05,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "Patterns observed with individual biomarkers confirmed in analysis across biomarkers leveraging Principal Component Analysis",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fae4e9eb-ceec-4786-8619-0fb98417336c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.55,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "*Graph produced the first Principal component from each pathway",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32d4fbce-a647-4a1f-a659-abdedd6f98c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "NurOwn decreases Neuroinflammation and Neurodegeneration, and increases Neuroprotection over 20 weeks (BCT-002)",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7966117e-b7fe-4652-a613-26cff1e9318f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALS Phase 3: Biomarker Evaluation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86cf3563-7b7e-4c5b-ae7d-95d3b23c1e9c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "52b96277-0cd1-415d-85fc-06ded87fc9ad",
      "evidence": "The slide presents data and findings related to a specific study, indicating that the audience is likely researchers or professionals in the field of ALS.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "Principal Component Analysis",
      "slug": null,
      "matchId": "10f200d5-8833-4c8b-b651-edf396f63568",
      "evidence": "Explicitly mentioned in title and body text as the analytical method used.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 6,
      "beatId": "1e09c995-6c2c-4ea3-94d4-8282e303405f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 6-14 present NurOwn as a potential solution",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 13,
      "from": 9,
      "beatId": "49ef375b-ea97-4105-b41e-dcea952fb555",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "Slides 9-13 summarize key findings",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 3,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "bce1965c-83ec-40d6-9c4c-8bfd12826169",
      "evidence": "Slides 3 and 10 present before-after comparisons",
      "position": 0,
      "objective": "Show the effect of NurOwn treatment on biomarkers",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}